⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151226 | 0.88 | — | — | |
| SCHEMBL6676332 | 0.78 | — | — | |
| SCHEMBL330407 | 0.75 | — | — | |
| SCHEMBL1301286 | 0.75 | — | — | |
| SCHEMBL39492 | 0.72 | — | — | |
| SCHEMBL3234893 | 0.72 | — | — | |
| Tert-Butanol SCHEMBL282 | 0.72 | — | — | |
| Tert-Butanol SCHEMBL20503401 | 0.72 | ALDH1A1 (0.46) | — | |
| Tert-Butanol SCHEMBL788666 | 0.72 | ALDH1A1 (0.46) | — | |
| SCHEMBL4990272 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368889-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-09-28 | — | — | EP | claimed |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2011-09-08 | — | — | US | claimed |
| EP-2357182-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-08-17 | — | — | EP | claimed |
| EP-2100891-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2009-09-16 | — | — | EP | claimed |
| EP-1532138-B1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2008-11-19 | — | — | EP | claimed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | claimed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | claimed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | claimed |
| EP-1495016-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | Astex Technology Limited (GB) | 2005-01-12 | — | — | EP | claimed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | claimed |
| WO-2003087087-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | ASTEX TECHNOLOGY LIMITED (GB) | 2003-10-23 | — | — | WO | claimed |
| EP-0760388-A2 | Polyester resin powder coating compositions | TIOXIDE SPECIALTIES LIMITED (GB) | 1997-03-05 | — | — | EP | claimed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-10319605-B2 | Semiconductor treatment composition and treatment method | JSR CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| EP-3444238-A2 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | Sato Pharmaceutical Co., Ltd. (JP) | 2019-02-20 | — | — | EP | disclosed |
| EP-2878594-B1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMA (JP) | 2018-11-28 | — | — | EP | disclosed |
| WO-2003087087-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | ASTEX TECHNOLOGY LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| US-6552225-B1 | Such as n-(2,3-dichloro-4-(methylaminosulphonyl)phenyl)-3,3,3-trifluoro-2-hydroxy-2 -methylpropanamide; diabetes, obesity, lactic acidaemia | ASTRAZENECA AB (SE) | 2003-04-22 | — | — | US | disclosed |
| US-5208380-A | Catalytic dehydration of isopropanolamine | KOEI CHEMICAL CO., LTD. (JP) | 1993-05-04 | — | — | US | disclosed |
| US-3970647-A | Bis-(triazinylamino)stilbene compounds | SANDOZ LTD. (CH) | 1976-07-20 | — | — | US | disclosed |